Ahmed Dahmani
Overview
Explore the profile of Ahmed Dahmani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
754
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Komar Z, Verkaik N, Dahmani A, Montaudon E, Kanaar R, Houtsmuller A, et al.
NPJ Breast Cancer
. 2025 Feb;
11(1):17.
PMID: 39962055
Breast cancer is the most common cancer amongst women worldwide, however clinically validated chemotherapy response biomarkers that can accurately predict treatment response in patients are largely lacking. Therefore, in this...
2.
Reinhold W, Marangoni E, Elloumi F, Montagne R, Varma S, Wang Y, et al.
Cancer Res Commun
. 2025 Feb;
5(2):375-388.
PMID: 39932272
Acetalax and bisacodyl represent a prospective novel drug mechanism-of-action type, affect mitochondrial function and affect tumor growth in vivo. Their activity may be predicted by TRPM4 but with more accuracy...
3.
Pottier C, Montero-Ruiz L, Jehay R, Wery C, Baiwir D, Mazzucchelli G, et al.
Cancer Commun (Lond)
. 2025 Jan;
PMID: 39801257
No abstract available.
4.
Remy D, Antoine-Bally S, de Toqueville S, Jolly C, Mace A, Champenois G, et al.
Dev Cell
. 2024 Dec;
PMID: 39729986
The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway is frequently hyperactivated in triple-negative breast cancers (TNBCs) associated with poor prognosis and is a therapeutic target in breast cancer management....
5.
Gruel N, Quignot C, Lesage L, El Zein S, Bonvalot S, Tzanis D, et al.
Nat Commun
. 2024 Sep;
15(1):7941.
PMID: 39266532
Dedifferentiated liposarcoma (DDLPS) is the most frequent high-grade soft tissue sarcoma subtype. It is characterized by a component of undifferentiated tumor cells coexisting with a component of well-differentiated adipocytic tumor...
6.
El-Botty R, Morriset L, Montaudon E, Tariq Z, Schnitzler A, Bacci M, et al.
Nat Commun
. 2023 Jul;
14(1):4221.
PMID: 37452026
Resistance to endocrine treatments and CDK4/6 inhibitors is considered a near-inevitability in most patients with estrogen receptor positive breast cancers (ER + BC). By genomic and metabolomics analyses of patients'...
7.
Passeri T, Gutman T, Hamza A, Adle-Biassette H, Girard E, Beaurepere R, et al.
J Neurosurg
. 2023 Apr;
139(5):1270-1280.
PMID: 37029667
Objective: Chordomas are rare bone neoplasms characterized by a high recurrence rate and no benefit from any approved medical treatment to date. However, the investigation of molecular alterations in chordomas...
8.
Ter Brugge P, Moser S, Bieche I, Kristel P, Ibadioune S, Eeckhoutte A, et al.
Nat Commun
. 2023 Apr;
14(1):1958.
PMID: 37029129
The high frequency of homologous recombination deficiency (HRD) is the main rationale of testing platinum-based chemotherapy in triple-negative breast cancer (TNBC), however, the existing methods to identify HRD are controversial...
9.
El-Botty R, Vacher S, Mainguene J, Briaux A, Ibadioune S, Dahmani A, et al.
Mol Oncol
. 2023 Feb;
17(10):2017-2028.
PMID: 36852691
Triple negative breast cancers (TNBCs) represent 15-20% of all breast cancers and are associated with higher recurrence and distant metastasis rate. Standard of care for early stage TNBC is anthracyclines...
10.
Passeri T, Dahmani A, Masliah-Planchon J, El Botty R, Courtois L, Vacher S, et al.
Front Oncol
. 2022 Dec;
12:960720.
PMID: 36505864
Background: Management of advanced chordomas remains delicate considering their insensitivity to chemotherapy. Homozygous deletion of the regulatory gene has been described as the most frequent genetic alteration in chordomas and...